Research summary, original research, 2016

A safety radiation marker in the cardiac catheterization lab

Kostakou PM, Damaskos DS, Dagre AG, Makavos GA, Olympios CD. Acta cardiologica. 2016

Read the original paper

In plain language

In 794 coronary procedures performed by three interventional cardiologists, each operator received about 0.06 mSv per procedure, and patient dose-area product related to operator dose at roughly 113:1, proposed as a rough marker for estimating operator dose.

At a glance

Type of study
Original research, Dosimetry measurement study
Who was studied
Interventional cardiologists, Patients
Size
n = 794 patients (procedures) with three interventional cardiologists
Summary based on
the abstract

What it found

  • The ratio between radiation exposure (dose-area product) and the dose finally absorbed by each operator was 113:1, proposed as a safety marker for estimating operator dose.

    Key figures: 113:1 μGym2/mSv

  • Average operator dose per procedure was 0.06 mSv.

    Key figures: 0.06 mSv per procedure

  • Total radiation exposure per angiographer across all procedure types was about 1.72 million μGym2 (median values).

    Key figures: 1,724,557.5 μGym2 (median)

  • Elective CRA plus percutaneous coronary intervention (PCI) procedures accounted for the highest exposure per cardiologist, higher than diagnostic CRA or primary PCI.

    Key figures: 833,371 μGym2 elective CRA+PCI vs 562,936 μGym2 CRA vs 328,250 μGym2 primary CRA+PCI

Limits to keep in mind

Only three interventional cardiologists at a single, unnamed centre; the abstract does not describe dosimeter placement, shielding used, or how absorbed dose was measured, and some units (e.g. 15,253) are unreported.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.